JANE BUCHAN - 15 May 2024 Form 4 Insider Report for Immix Biopharma, Inc. (IMMX)

Role
Director
Signature
/s/ Ilya Rachman as Attorney-In-Fact for Jane Buchan
Issuer symbol
IMMX
Transactions as of
15 May 2024
Transactions value $
$0
Form type
4
Filing time
20 May 2024, 17:25:45 UTC
Previous filing
03 Jan 2024
Next filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMMX Common Stock Award $0 +1,332 +6.7% $0 21,332 15 May 2024 Direct F1, F2
transaction IMMX Common Stock Award +1,127 +5.3% 22,455 20 May 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMMX Stock Option (Right to Buy) Award $0 +20,436 $0 20,436 15 May 2024 Common Stock 20,436 $2.47 Direct F1
transaction IMMX Stock Option (Right to Buy) Award $0 +24,153 $0 24,153 15 May 2024 Common Stock 24,153 $2.47 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024.
F2 Restricted Stock Awards which will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.
F3 Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity.
F4 The Stock Option will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Remarks:

See Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on December 15, 2021.